BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 24840285)

  • 21. Biological Therapies: Effects of Proinflammatory Pathways and their Inhibition on the Myocardium of Rheumatoid Athritis Patients.
    Obermair F; Pieringer H
    Curr Med Chem; 2015; 22(16):1911-29. PubMed ID: 25666787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
    Gottlieb AB; Kalb RE; Langley RG; Krueger GG; de Jong EM; Guenther L; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Menter A
    J Drugs Dermatol; 2014 Dec; 13(12):1441-8. PubMed ID: 25607786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.
    Bissonnette R; Maari C; Barber K; Lynde CW; Vender R
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1576-81. PubMed ID: 25600828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritis.
    Briot K; Rouanet S; Schaeverbeke T; Etchepare F; Gaudin P; Perdriger A; Vray M; Steinberg G; Roux C
    Joint Bone Spine; 2015 Mar; 82(2):109-15. PubMed ID: 25557658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravitreal Adalimumab in Active Noninfectious Uveitis: A Pilot Study.
    Hamam RN; Barikian AW; Antonios RS; Abdulaal MR; Alameddine RM; El Mollayess G; Mansour AM
    Ocul Immunol Inflamm; 2016 Jun; 24(3):319-26. PubMed ID: 25549063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.
    Mease P; Sieper J; Van den Bosch F; Rahman P; Karunaratne PM; Pangan AL
    Arthritis Rheumatol; 2015 Apr; 67(4):914-23. PubMed ID: 25545240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.
    Navarro Coy NC; Brown S; Bosworth A; Davies CT; Emery P; Everett CC; Fernandez C; Gray JC; Hartley S; Hulme C; Keenan AM; McCabe C; Redmond A; Reynolds C; Scott D; Sharples LD; Pavitt S; Buch MH
    BMC Musculoskelet Disord; 2014 Dec; 15():452. PubMed ID: 25539805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
    Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
    J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. I've been taking methotrexate for my rheumatoid arthritis (RA) for several years, but it doesn't seem to be helping my symptoms. My doctor suggested adding a biologic response modifier (BRM) drug, such as etanercept (Enbrel) or adalimumab (Humira) to my treatment plan, but I've heard that BRMs can increase cancer risk.
    Duke Med Health News; 2014 Nov; 20(11):8. PubMed ID: 25518068
    [No Abstract]   [Full Text] [Related]  

  • 30. The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.
    Osman M; Pagnoux C; Dryden DM; Storie D; Yacyshyn E
    PLoS One; 2014; 9(12):e115026. PubMed ID: 25517966
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
    JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register.
    Forsblad-d'Elia H; Bengtsson K; Kristensen LE; Jacobsson LT
    Rheumatology (Oxford); 2015 Jul; 54(7):1186-93. PubMed ID: 25505001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
    Rheumatology (Oxford); 2015 Jul; 54(7):1170-6. PubMed ID: 25504896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Use of Biologic Therapies in Uveitis.
    Schwartzman S; Schwartzman M
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):307-16. PubMed ID: 25431348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy.
    Khan N; Asim H; Lichtenstein GR
    Expert Opin Drug Saf; 2014 Dec; 13(12):1699-708. PubMed ID: 25406728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.
    ACCESS Trial Group
    Arthritis Rheumatol; 2014 Nov; 66(11):3096-104. PubMed ID: 25403681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity.
    Lories RJ; de Vlam K
    Expert Opin Biol Ther; 2014 Dec; 14(12):1825-36. PubMed ID: 25366335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative efficiencies of the 7 rheumatoid arthritis Core Data Set measures to distinguish active from control treatments in 9 comparisons from clinical trials of 5 agents.
    Pincus T; Richardson B; Strand V; Bergman MJ
    Clin Exp Rheumatol; 2014; 32(5 Suppl 85):S-47-54. PubMed ID: 25365089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
    Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
    Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians.
    Khraishi MM
    Ther Adv Musculoskelet Dis; 2014 Oct; 6(5):159-68. PubMed ID: 25342995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.